Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2006-02-07
2011-10-18
Kemmerer, Elizabeth C (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S133100, C424S135100, C424S141100, C530S387100, C530S387900, C530S388100, C530S389100
Reexamination Certificate
active
08038995
ABSTRACT:
The invention pertains to a human N-type calcium channel isoform, hα1B+SFVG, which is involved in central nervous system signaling, and nucleic acids relating thereto. The present invention also includes fragments and biologically functional variants of the human hα1B+SFVGchannel. Also included are human N-type calcium channel hα1B+SFVGsubunit inhibitors which inhibit human N-type calcium channel hα1B+SFVGsubunit activity by inhibiting the expression or function of human N-type calcium channel hα1B+SFVGsubunit. The invention further relates to methods of using such nucleic acids, polypeptides, and inhibitors in the treatment and/or diagnosis of disease, such as in methods for treating stroke, pain, e.g., neuropathic pain, and traumatic brain injury.
REFERENCES:
patent: 4917887 (1990-04-01), Hauptmann et al.
patent: 5429921 (1995-07-01), Harpold et al.
patent: 6140485 (2000-10-01), Franco et al.
patent: 6218364 (2001-04-01), Harbeson et al.
patent: 6353091 (2002-03-01), Lipscombe et al.
patent: 6492324 (2002-12-01), Hinuma et al.
patent: 7018832 (2006-03-01), Lipscombe et al.
patent: WO-9304083 (1993-03-01), None
patent: WO-9504822 (1995-02-01), None
patent: WO-9811131 (1998-03-01), None
GenBank Accession No. M94172, Oct. 31, 1994.
GenBank Accession No. M94173, Oct. 31, 1994.
Hines et al, Neural Computation 12: 995-1007 (2000).
Jones, J. Gen. Physiol. 94: 151-167 (1989).
Ligon et al., J. Biol. Chem. 273(22): 13905-13911 (1998).
Lin et al., Neuron 18: 153-166, 1997.
Lin et al., J. Neuroscience 19(13): 5322-5331 (1999).
Lipscombe et al. Nature 340:639-642, 1989.
Mainen et al, Science 268: 1503-1509 (1995).
Mathur et al. J. Gen. Physiol. 109: 191-199 (1997).
McCarthy et al, J. Neuroscience 12: 2225-2234 (1992).
Mintz et al., Neuron 9: 85-95 (1992).
Nakai et al., Proc. Natl. Acad. Sci. USA 91: 1014-1018 (1994).
New England BioLabs Catalog 1995, pp. 106-108.
Soong et al., Science 260: 1133-1136 (1993).
Soong et al., Society for Neuroscience Abstracts vol. 20 No. 1-2, Nov. 13-18, 1994, p. 70.
Starr et al., Proc. Natl. Acad. Sci. USA 89: 5621-5625 (1991).
Sutton et al., Soc. Neurosci. Abs. 24:21, 1998.
Tang et al, J. Gen. Physiol. 109: 301-311 (1997).
Williams et al., Science 257: 389-395 (1992).
Yu et al., Proc. Natl. Acad. Sci. USA 89: 10494-10498 (1992).
Zhang et al., Nature 372: 97-100 (1994).
Lipscombe Diane
Schorge Stephanie
Edwards Angell Palmer & & Dodge LLP
Kemmerer Elizabeth C
Scion Pharmaceuticals, Inc.
LandOfFree
Human N-type calcium channel isoform and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human N-type calcium channel isoform and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human N-type calcium channel isoform and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256830